A medtech expert explains why a recall is a quality event and a national shortage is a design decision made years earlier.

Patent attorney Jay Halt explains how medtech companies should align IP strategy with FDA compliance to avoid unenforceable patents and regulatory issues.

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests Quest Diagnostics (NYSE:DGX) reported double-digit revenue ...

Australia has slipped behind countries including the United States, Thailand and Serbia in a major global women’s health ...

and 28: Women’s Enterprise Development Center free course, Bookkeeping & QuickBooks: Know Your Numbers, Grow Your Business (two-part series), 6-8 p.m., 3 Neptune Road, Poughkeepsie. The course ...

Where Citi’s DCM franchise demonstrated command of the bond market, its financing solutions platform showed something equally ...

Bouzkova had been runner-up in three other Hologic WTA Tour singles finals in her career to date, including earlier this year in Guadalajara, Mexico to Sloane Stephens.

Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's ...